Anna Berkenblit
Chief Scientific and Medical Officer @ Pancreatic Cancer Action Network
United States
Needham
Biotechnology
Clinical Research, Medicine, Clinical Development, Drug Development, Oncology, Clinical Trials, Pharmaceutical Industry, Medical Affairs, GCP, Biotechnology, Drug Discovery, Therapeutic Areas
Experience
Chief Scientific and Medical Officer
Pancreatic Cancer Action Network
Chief Scientific and Medical Officer
Pancreatic Cancer Action Network
Board Member
TORL BioTherapeutics LLC
Independent Board Director
Nested Therapeutics
Independent Board Director
Surrozen
SVP and Chief Medical Officer
ImmunoGen, Inc.
Waltham, MA
Led the clinical development of the ADC portfolio, culminating in accelerated approval of mirvetuximab soravtansine (Elahere) -- first-in-class FRalpha ADC for ovarian cancer, followed by positive confirmatory MIRASOL trial, with Elahere the first novel agent to demonstrate an overall survival benefit in platinum resistant ovarian cancer. Advanced pivekimab sunirine CD123 ADC into monotherapy pivotal trial in BPDCN and combination strategy in AML.
Chief Medical Officer
ImmunoGen, Inc.
Waltham, MA
Built out clin dev, clin ops, pharmacovigilance, biostats/programming, and medical affairs functions to advance ADC pipeline
Sr VP Head of Clinical Development
H3 Biomedicine
Translated patient focused genomic drug discovery platform into experimental clinical trials. Led the design and supported implementation of early phase clinical oncology studies for assessing product pharmacology and safety as well as Phase I/II proof of concept studies in highly stratified and enriched patient populations.
Head of Clinical Research
AVEO
Cambridge, MA
Led clinical development efforts for tivozanib RCC NDA and ODAC. Contributed to clinical development plans for oncology pipeline compounds.
Asset Team Lead
Pfizer
Team leader for neratinib phase 3 breast cancer program
Medical Director
Pfizer
Medical Monitor for Torisel program and neratinib
Associate Medical Director
Wyeth
Medical Monitor for Torisel; led clinical efforts for global registration of Torisel for RCC; assisted with MCL filing in EU.
Director, Phase I Oncology Clinical Trials, BIDMC/DFHCC
Beth Israel Deaconess Medical Center
Heme/Onc Fellowship
Beth Israel Deaconess Medical Center
Education
Harvard Medical School
Yale University
Molecular Biochemistry and Biophysics
Anna Berkenblit's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.